Pharmaceuticals

A new partnership aims to commercialize Arbli™, the first liquid losartan, leveraging a digital platform to solve patient adherence and capture market share.

Impressive new trial data for MDNA11 could disrupt the multi-billion dollar immunotherapy market, offering real hope where standard treatments now fail.

A new partnership between Telix and Varian aims to fuse precision diagnostics with adaptive radiotherapy, a strategic move set to disrupt the cancer care market.

India's new Labour Code 2025 is forcing a strategic pivot. Discover how firms are turning regulatory mandates into a competitive edge for productivity.

With $47.5M and a veteran CEO, PsiThera is using its advanced AI platform to develop oral medicines for diseases long-dominated by injectable biologics.

Professor Youmin Xi's recent honor signals more than academic success. It marks a strategic blueprint for cultivating the next generation of life science leaders.

A novel drug for heart failure shows promising safety and efficacy data, potentially disrupting a multi-billion dollar market and validating a key investor's strategy.

A Chinese biotech is pioneering next-gen cancer drugs that promise higher precision and fewer side effects. Is this the future of oncology treatment?

Beyond a simple FDA approval, Amneal's entry into the epinephrine vial market is a calculated move to fix a broken supply chain and drive growth.

A regulatory filing from Balyasny Asset Management reveals intense investor activity as a bidding war for narcolepsy drugmaker Avadel heats up.

A newly validated 'longevity protein' is fueling a biotech gold rush, but can companies turn breakthrough science into viable medicine? An inside look.

A strategic investment firm's move signals strong confidence in the closing of Avadel's multi-billion dollar deal, spotlighting its blockbuster sleep drug.

Trinity Consultants' acquisition of CEQA/NEPA expert Meridian is more than a regional deal; it's a strategic move with deep implications for biopharma.

Stunning trial data reveals an immunotherapy combo that slashes myeloma progression by 83%, offering not just longer life but a better quality of life.

LRN appoints Bob Lemmond as CEO, a strategic move signaling a deeper push into data-driven ethics amid rising AI regulations and market complexity.

Beyond a simple product launch, a strategic acquisition is fueling innovations in drug delivery that could transform patient care for millions worldwide.

A new narcolepsy drug could finally offer patients what they've been missing: a single nightly dose with low sodium, transforming lives and the market.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

A fierce bidding war for Avadel Pharmaceuticals reveals the high value of its key drug, as filings from giants like State Street highlight M&A transparency.